

Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial


Susan Halabi et al. Kidney Cancer Journal, 19(3), 64-72, 2021

DOI.org/10.52733/kcj19n3-a1


SUPPLEMENTARY DATA

Figures.


Supplementary Figure 1. CONSORT diagram for the ASPEN clinical trial and biomarker studies included.




Supplementary Figure 2A. Kaplan-Meier Overall Survival Curves by Tissue Biomarkers (pAkt (2+ cutoff), pS6 (2+ cutoff), HIF-1 α (2+ cutoff), c-kit (2+ cutoff), and c-MET (2+ cutoff)).



Supplementary Figure 2B. Kaplan-Meier PFS Curves by Tissue Biomarkers (pAkt (2+ cutoff), pS6 (2+ cutoff), HIF-1 α (2+ cutoff), c-kit (2+ cutoff), and c-MET (2+ cutoff)).



Supplementary Figure 3A. Kaplan-Meier Overall Survival Curves by Treatment Assignment and Tissue Biomarkers (pAkt, pS6, HIF-1 α , c-kit, and c-MET). Note that for pAkt there is no patient in the 2+, Sunitinib group.



Supplementary Figure 3B. Kaplan-Meier Progression-Free Survival Curves by Treatment Assignment and Tissue Biomarkers (pAkt, pS6, HIF-1 α , c-kit, and c-MET).

